Find Clinical Trial

Efficacy and safety of bumetanide oral liquid formulation in children and adolescents aged from 7 to less than 18 years old with Autism Spectrum Disorder


← Back
Study Phase

Phase 3

Therapeutic Area

Neuropsychiatric Diseases

IndicationAutism Spectrum Disorder
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

BUMETANIDE,
S095008

Active Substance CodeS095008
Protocol CodeCL3-95008-001
EudraCT Code2017-004419-38
NCT CodeNCT03715166


More information

https://autism-studies.com



Documents and links

Results are not yet available.




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2020 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility